BioNexus Gene Lab (BGLC) Receivables - Net (2020 - 2026)

BioNexus Gene Lab's Receivables - Net history runs 7 years deep, the most recent figure standing at $79860.0 for Q1 2026.

• In Q1 2026, Receivables - Net fell 94.46% year-over-year to $79860.0; the TTM figure through Mar 2026 stood at $79860.0 (down 94.46% YoY), while the FY2025 annual figure was $505885.0, down 63.25% from the prior year.
• Receivables - Net came in at $79860.0 for Q1 2026 at BioNexus Gene Lab, down from $505885.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $3.0 million in Q1 2022 to a low of $79860.0 in Q1 2026.
• A 5-year average of $1.6 million and a median of $1.4 million in 2025 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net jumped 87.47% in 2025 and sank 94.46% in 2026, its largest moves.
• BioNexus Gene Lab's Receivables - Net stood at $2.9 million in 2022, then tumbled by 72.12% to $799674.0 in 2023, then soared by 72.14% to $1.4 million in 2024, then slumped by 63.25% to $505885.0 in 2025, then tumbled by 84.21% to $79860.0 in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $79860.0, $505885.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison